Intas eyes market expansion for cut-price Vidaza in India
This article was originally published in Scrip
Executive Summary
Intas Pharmaceuticals, which has launched the first cut-price generic version of Celgene's anticancer, Vidaza (azacitidine) in India, hopes to expand access to the product through a string of measures including potential co-marketing alliances.